UNSPSC 51285202: Epiroprim

This classification denotes a folate antagonist and antiprotozoal agent with the molecular structure C19H23N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9G69D95443 chemically known as 2,4-diamino-5-(3,5-diethoxy-4-pyrrol-1-ylbenzyl)pyrimidine, but more commonly known as epiroprim, which bears US NIH Compound Identifier 68916. European Medicines Agency schedules Epiroprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06570MIG.

The term EPIROPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, no. 5 1981, list 21).

UNSPSC 51285202 Epiroprim is a Commodity-tier code that identifies pharmaceutical products, but recent state and local opportunities tagged under this code span a broader set of health-related procurement activities including naloxone distribution, pharmacy benefit program management, medical and first aid supplies for emergency response, and generic pharmaceuticals available through cooperative purchasing vehicles. State and local governments are buying these products to support public health initiatives, emergency medical services, and employee and client health benefits across health departments, fire departments, and multistate cooperative purchasing organizations. The issuing bodies include county health departments, municipal fire departments, state health and human services commissions, and cooperative purchasing alliances that aggregate buying power across multiple state and local members.

Geographic activity centers on Florida, Texas, Minnesota, and Oregon based on recent solicitations. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The City of Tampa issued an ITB (26P00145) on March 25, 2026 (due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000.00 and a 5 percent small local business enterprise (SLBE) bid discount. The Texas Health and Human Services Commission released an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity without pharmacy benefit manager intermediaries. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with performance effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness.